Henry Schein Raises Full-Year Profit Guidance Following Q3 Beat (HSIC)

Henry Schein, Inc. raised its full-year 2026 non-GAAP earnings per share guidance above previous analyst projections following third-quarter results that showed profit growing faster than revenue. The healthcare distributor confirmed its full-year sales growth outlook and introduced guidance for the fourth quarter. Net sales rose compared with the prior-year period, landing in line with expectations, while adjusted earnings per share exceeded consensus forecasts by a wide margin.

The earnings outperformance reflects operational efficiency programs and a shift toward higher-margin products and services. Henry Schein has focused on expanding its specialty offerings, such as dental implants, orthodontics, and endodontics, alongside recurring practice management software. These segments carry stronger margins than traditional supply distribution. The company has also concentrated on streamlining operations and lifting warehouse productivity following recovery from a late-2023 cyber incident.

Alongside financial results reported on November 3, Henry Schein announced executive leadership changes that took effect November 4. Continuity remains a focal point for the distributor as it navigates market conditions, including tariff pressures on imported medical and dental supplies and practice-level spending headwinds driven by staffing costs and higher interest rates.

Positive earnings revisions following the report prompted Zacks Investment Research to upgrade the stock to a Zacks Rank #2 (Buy). Zacks analysts highlighted improving earnings trends, projecting the company's annual earnings per share to grow 10.6% this year compared to an industry average of 5.3%, alongside projected annual sales growth of 5%. Analysts also pointed to an asset utilization ratio of 1.21, outpacing the broader industry average of 0.77.